These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8866499)

  • 1. Postencephalitic stereotyped involuntary movements responsive to L-Dopa.
    Picard F; de Saint-Martin A; Salmon E; Hirsch E; Marescaux C
    Mov Disord; 1996 Sep; 11(5):567-70. PubMed ID: 8866499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Parkinsonian syndrome and post-encephalitic stereotyped involuntary movements responsive to L-dopa].
    Picard F; Hirsch E; Salmon E; Marescaux C; Collard M
    Rev Neurol (Paris); 1996 Apr; 152(4):267-71. PubMed ID: 8763655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
    Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y
    J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K; Ferger B
    Neuroscience; 2009 Mar; 159(1):16-20. PubMed ID: 19146929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopa-responsive parkinsonism phenotype of spinocerebellar ataxia type 2.
    Lu CS; Wu Chou YH; Yen TC; Tsai CH; Chen RS; Chang HC
    Mov Disord; 2002 Sep; 17(5):1046-51. PubMed ID: 12360557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys.
    Stephenson DT; Meglasson MD; Connell MA; Childs MA; Hajos-Korcsok E; Emborg ME
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1257-66. PubMed ID: 15980058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Akinetic mutism from recurrent hydrocephalus: successful treatment with levodopa, bromocriptine and trihexyphenidyl].
    Watahiki Y; Narita S; Kurahashi K; Tanaka T; Matsunaga M
    No To Shinkei; 1987 Oct; 39(10):977-82. PubMed ID: 3435688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
    Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
    Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
    [No Abstract]   [Full Text] [Related]  

  • 16. [Experience with the use of parlodel in the treatment of Parkinson patients].
    Stoliarova LG; Kadykov AS; Shvedkov VV; Pivovarova VM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(2):219-22. PubMed ID: 3705825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dystonia in ataxia telangiectasia: report of a case with putaminal lesions and decreased striatal [123I]iodobenzamide binding.
    Koepp M; Schelosky L; Cordes I; Cordes M; Poewe W
    Mov Disord; 1994 Jul; 9(4):455-9. PubMed ID: 7969215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
    Delfino MA; Stefano AV; Ferrario JE; Taravini IR; Murer MG; Gershanik OS
    Behav Brain Res; 2004 Jul; 152(2):297-306. PubMed ID: 15196797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.